Anpac Bio Announces Change of Auditor

By Dr. Matthew Watson

SAN JOSE, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the resignation of Ernst & Young Hua Ming LLP ("EY"), which previously was the independent registered public accounting firm of Anpac Bio, on November 3, 2020 and the appointment of Friedman LLP ("Friedman") as the Company's independent registered public accounting firm on December 2, 2020 to conduct the audit for the fiscal year ended December 31, 2020.   The appointment of Friedman has been approved by both the audit committee and the board of directors (the "Board") of the Company. The change was not made due to any disagreements with EY.

Go here to see the original:
Anpac Bio Announces Change of Auditor

Related Post

categoriaGlobal News Feed commentoComments Off on Anpac Bio Announces Change of Auditor | dataDecember 5th, 2020


This author published 3404 posts in this site.


FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.

Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research